Articles by Michael Morris, MD
The panelists examine the existing data for T cell engagers in CRPC and how the data might affect clinical practice.
The panelists discuss T cell engagers, including an introduction and discussion of cytokine release syndrome.
The panel discusses the emerging field of PSMA-targeted alpha radioligand therapy, with a focus on HK2.
The panel discusses the results of PEACE-3, which evaluated enzalutamide with or without radium-223 for MCRPC.
The panel discusses two significant trials in metastatic hormone-sensitive prostate cancer.
Part 2 of the Radioligands session from Uromigos Live 2024 features a discussion on the SPLASH results from ESMO 2024.
The first part of five segments from the Uromigos Live 2024 session on radioligands.
In the final segment of this series, Drs. Morris, Garmezy, and Chen discuss the use of novel radiopharmaceuticals.
In the fourth part of this series, the panelists discuss barriers to the use of radium-223 and other radioligands.
In part 3 of this series, the panelists review the latest game-changing studies in prostate cancer and CRPC from ESMO 2024.
In the second part of this series, the decision-making process of considering ADT and doublet or triplet therapy is weighed.
In the first segment of this roundtable series, the panelists discuss the use of PSMA PET scans and ADT for CRPC.
The Radioligands panel at Uromigos Live & Unplugged 2024 explored the role of RLT in prostate cancer treatment.
Watch the T Cell Directed Therapy in Prostate Cancer session from Uromigos Live 2024.
Dr. Morris discusses a phase 1 study of JNJ-6420 for patients with mCRPC who received at least prior ARPI.
The panel shares insights on future advancements in the field.
The panel discussed the "innovative design" of the phase 2 ENZA-p study presented at ESMO 2023.
The panel discusses treatment-related adverse events, including hematologic toxicities, xerostomia, and more.
The panel discuss patient interest in receiving radioligand therapy in the context of cost and access challenges.
The panel discusses results of the phase 3 PSMAfore study presented at ESMO 2023.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.